![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/01/23/2813976/0/en/Locus-Biosciences-Announces-23-9-Million-in-Funding-from-BARDA-to-Support-First-Phase-2-Trial-of-CRISPR-engineered-Bacteriophage-Therapy.html
https://www.globenewswire.com/news-release/2022/09/13/2514936/0/en/Locus-Biosciences-Announces-First-Patient-Treated-in-the-ELIMINATE-Registrational-Phase-2-3-Trial-of-LBP-EC01-for-Urinary-Tract-Infections.html
https://www.fiercebiotech.com/biotech/jj-backed-locus-closes-35m-financing-crispr-based-antimicrobial-drugs
https://www.globenewswire.com/news-release/2022/05/18/2445897/0/en/Locus-Biosciences-Announces-35-Million-Financing.html
https://www.globenewswire.com/news-release/2021/10/19/2316376/0/en/Locus-Biosciences-Secures-Financing-of-up-to-25-Million-from-Hercules-Capital.html
https://www.globenewswire.com/news-release/2021/02/24/2181504/0/en/Locus-Biosciences-completes-first-of-its-kind-controlled-clinical-trial-for-CRISPR-enhanced-bacteriophage-therapy.html